Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NYSE:DNA NASDAQ:KRYS NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$64.06-1.9%$45.23$30.04▼$71.13$5.52B1.822.02 million shs2.41 million shsDNAGinkgo Bioworks$12.83+13.3%$8.94$5.00▼$16.85$754.57M1.481.44 million shs2.40 million shsKRYSKrystal Biotech$151.83+2.5%$136.57$122.80▼$219.34$4.38B0.67285,771 shs64,329 shsRVMDRevolution Medicines$38.22-0.5%$39.11$29.17▼$62.40$7.12B1.061.62 million shs481,622 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.31%+15.79%+47.64%+66.53%+19.74%DNAGinkgo Bioworks+11.60%+14.03%+32.49%+50.23%-15.46%KRYSKrystal Biotech+0.41%-1.54%+11.80%-12.27%-27.29%RVMDRevolution Medicines+0.31%+0.13%-3.13%+4.23%-16.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics2.8486 of 5 stars3.31.00.00.03.83.30.6DNAGinkgo Bioworks0.6878 of 5 stars1.01.00.00.02.52.50.6KRYSKrystal Biotech4.5305 of 5 stars3.51.00.04.72.23.31.9RVMDRevolution Medicines4.5498 of 5 stars4.53.00.04.72.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$71.7512.00% UpsideDNAGinkgo Bioworks 2.00Hold$8.50-33.73% DownsideKRYSKrystal Biotech 3.00Buy$213.7540.79% UpsideRVMDRevolution Medicines 3.00Buy$68.9180.30% UpsideCurrent Analyst Ratings BreakdownLatest DNA, CRSP, KRYS, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025RVMDRevolution MedicinesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.007/9/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.007/8/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.006/25/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/24/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.00 ➝ $73.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M158.07N/AN/A$22.64 per share2.83DNAGinkgo Bioworks$227.04M3.31N/AN/A$13.17 per share0.97KRYSKrystal Biotech$333.45M13.16$4.77 per share31.81$32.90 per share4.61RVMDRevolution Medicines$11.58M614.79N/AN/A$13.47 per share2.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1636.4415.06N/A37.17%14.64%13.28%8/4/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)Latest DNA, CRSP, KRYS, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DNAGinkgo Bioworks-$1.44N/AN/AN/AN/AN/A8/6/2025Q2 2025RVMDRevolution Medicines-$1.14N/AN/AN/A$0.50 millionN/A8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.54N/AN/AN/A$6.44 millionN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A15.6415.64DNAGinkgo BioworksN/A4.884.88KRYSKrystal BiotechN/A9.659.27RVMDRevolution MedicinesN/A13.4613.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%DNAGinkgo Bioworks78.63%KRYSKrystal Biotech86.29%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%DNAGinkgo Bioworks9.72%KRYSKrystal Biotech13.70%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46086.36 million82.82 millionOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableRVMDRevolution Medicines250186.27 million170.99 millionOptionableDNA, CRSP, KRYS, and RVMD HeadlinesRecent News About These CompaniesRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Recommendation of "Buy" from AnalystsJuly 21 at 2:35 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Arizona State Retirement SystemJuly 19 at 4:13 AM | marketbeat.comBank of New York Mellon Corp Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)July 18, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Revolution Medicines (RVMD) with Buy RecommendationJuly 15, 2025 | msn.comRevolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at The Goldman Sachs GroupJuly 15, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Edgestream Partners L.P.July 14, 2025 | marketbeat.comRevolution Medicines and Iambic Announce Technology and Research ...July 11, 2025 | nasdaq.comRevolution Medicines and Iambic Therapeutics Announce ... - NasdaqJuly 11, 2025 | nasdaq.comIambic and Revolution Medicines Partner on AI Cancer Drug DiscoveryJuly 9, 2025 | genengnews.comGRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug CandidatesJuly 9, 2025 | finance.yahoo.comRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug CandidatesJuly 9, 2025 | globenewswire.comAllspring Global Investments Holdings LLC Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD)July 9, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Acquires 27,982 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)July 8, 2025 | marketbeat.comRevolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid TumorsJuly 6, 2025 | msn.comRevolution Medicines, Inc. (NASDAQ:RVMD) Position Boosted by WCM Investment Management LLCJuly 3, 2025 | marketbeat.comRevolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS (ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - NasdaqJuly 2, 2025 | nasdaq.comLeerink Partnrs Issues Optimistic Estimate for RVMD EarningsJuly 2, 2025 | marketbeat.comRevolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant TumorsJune 30, 2025 | globenewswire.comLunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)June 29, 2025 | marketbeat.comQ3 EPS Estimate for Revolution Medicines Raised by AnalystJune 27, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by AnalystsJune 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNA, CRSP, KRYS, and RVMD Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$64.06 -1.27 (-1.94%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Ginkgo Bioworks NYSE:DNA$12.83 +1.51 (+13.31%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Krystal Biotech NASDAQ:KRYS$151.82 +3.74 (+2.52%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Revolution Medicines NASDAQ:RVMD$38.22 -0.20 (-0.52%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Vertical Aerospace Stock Trades at Discount After VX4 Milestone GameStop: Clarity Brings Renewed Confusion for Meme Stock Analysts Are Backing Qualcomm: Is a Breakout Coming? TSLA Earnings Week: Can Tesla Break Through $350? D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.